BriaCell Therapeutics (NASDAQ:BCTX) Price Target Lowered to $15.00 at HC Wainwright

BriaCell Therapeutics (NASDAQ:BCTX) had its price target reduced by HC Wainwright from $18.00 to $15.00 in a research note published on Thursday, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for BriaCell Therapeutics’ FY2029 earnings at ($0.05) EPS.

BriaCell Therapeutics Stock Up 7.7 %

Shares of NASDAQ:BCTX opened at $0.65 on Thursday. The stock has a market cap of $11.87 million, a PE ratio of -0.52 and a beta of 1.31. The company’s fifty day moving average is $0.70 and its 200 day moving average is $1.52. BriaCell Therapeutics has a 52 week low of $0.46 and a 52 week high of $6.36.

Hedge Funds Weigh In On BriaCell Therapeutics

A hedge fund recently raised its stake in BriaCell Therapeutics stock. Onyx Bridge Wealth Group LLC increased its holdings in BriaCell Therapeutics Corp. (NASDAQ:BCTX) by 66.7% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 50,000 shares of the company’s stock after purchasing an additional 20,000 shares during the quarter. Onyx Bridge Wealth Group LLC owned 0.31% of BriaCell Therapeutics worth $143,000 as of its most recent filing with the Securities & Exchange Commission. 15.42% of the stock is owned by hedge funds and other institutional investors.

About BriaCell Therapeutics

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.